Endovascular Engineering Appoints Dan Rose as Chief Executive Officer

MENLO PARK, Calif. , Aug. 20, 2024 /PRNewswire/ -- Endovascular Engineering, Inc.

("E2"), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), has named Dan Rose as Chief Executive Officer (CEO). Former CEO and founding team member Mike Rosenthal will continue as Chief Operating Officer and remain on the company's Board of Directors. He will also continue in his role as Founder and General Partner at Inventure Group , LLC, where E2 was incubated.

Most recently, Mr. Rose served as CEO of LimFlow S.A.

, a pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). He joined LimFlow as the first employee and successfully guided the company through its acquisition by Inari Medical, Inc. He assembled a world-class team that developed and commercialized a practice-changing therapy for the treatment of late-stage CLTI, which resulted in an FDA approval and a landmark publication in the New England Journal of Medicine.

Previously, Mr. Rose served as Vice President and General Manager Europe for Direct Flow Medical, and led commercial and clinical activities at Sequana Medical AG. Earlier in his career, he held successive commercial leadership roles at Medtronic in Europe .

Mr. Rose has a BA and MA from the University of Virginia and an MBA from its Darden School of Business. "Endovascular Engineering continues to set the standard in clinical innovation and patient care, driven by the stead.